Cost Action CA 17140 Nano2Clinic
Cancer Nanomedicine - from the bench to the bedside
Laufzeit: 28.09.2018 - 27.09.2022
Nano2Clinic is the first, pan-European interdisciplinary network of representatives from academic institutions and small and medium enterprises including clinical research organizations (CROs) devoted to the development of nanosystems carrying anticancer drugs from their initial design, pre-clinical testing of efficacy, pharmacokinetics and toxicity to the preparation of detailed protocols needed for the first phase of their clinical studies. By promoting scientific exchanges, technological implementation and innovative solutions, the Action will provide a timely instrument to rationalize and focus research efforts at the EU level in dealing with the grand challenge of nanomedicine translation in cancer, one of the major and societal-burdening human pathologies.
The project is funded by EU grant Horizon 2020 under the number CA17140 and co-funded by the project executing agency EU-H2020.